Edoxaban monotherapy reduced primary net adverse events at 12 months in men but not in women with AF and CAD, with no significant sex interaction observed.
Does edoxaban monotherapy reduce primary net adverse events compared to edoxaban with an antiplatelet agent in patients with atrial fibrillation and chronic stable coronary artery disease?
In patients with AF and stable CAD, edoxaban monotherapy reduced net adverse events in men but not women, though the lack of a significant sex interaction indicates further research is needed to define sex-specific antithrombotic strategies.
Absolute Event Rate: 0% vs 0%
Edoxaban monotherapy reduced primary net adverse events at 12 months in men but not in women. No significant interaction with sex was observed. Further research is needed to identify sex-specific antithrombotic strategies for patients with AF and CAD. (Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease EPIC-CAD; NCT03718559).
Kim et al. (Sun,) reported a other. Edoxaban monotherapy reduced primary net adverse events at 12 months in men but not in women with AF and CAD, with no significant sex interaction observed.